Status and phase
Conditions
Treatments
About
177Lu-LNC1010(177Lu-EB-TATE-01) is a radiotherapeutic drug indicated in subjects with unresectable, metastatic somatostatin receptor (SSTR) positive tumors.
In this study, we designed and developed a new radioligand, EB-TATE-01 (second generation long-acting EB-TATE formula), through combining EB and altering the linker to further improve the pharmacokinetics and pharmacodynamics, leading to substantially enhanced radioligand therapy effect.
This is an open-label, non-controlled, non-randomized study to investigate the long-lasting radiolabeled somatostatin analogue based peptide receptor radionuclide therapy and evaluate response to 177Lu-LNC1010 in patients with advanced SSTR2-positive tumors. Different groups with doses of 2.22GBq (60 mCi), 3.33GBq (90mCi) and 4.99GBq (145mCi) of 177Lu-LNC1010 will be injected intravenously. All patients will undergo 68Ga-DOTA-Octreotide(TATE) PET/CT scans before and after the treatment.
Full description
Somatostatin receptor(SSTR), especially SSTR subtype 2 (SSTR2),has been a popular target for molecular imaging and radionuclide therapy in recent years. SSTR antagonists, such as LNC1010, have emerged as a new type of somatostatin analog, characterized by a low internalization rate and high tumor affinity. 68Ga-DOTA(68Ga-DOTA)-LNC1010 has been reported that it showed favorable biodistribution, high tumor uptake, and good tumor retention, resulting in high image contrast. SSTR2 has been found highly expressed in SSTR2-positive tumors, indicating the feasibility of Positron Emission Tomography(PET)/ CT with 68Ga-DOTA-conjugated peptides for imaging SSTR2 expression and peptide-receptor radionuclide therapy (PRRT) for the treatment option in SSTR2-positive tumors. However, a major problem in the therapeutic use of 177Lu-DOTA(177Lu-DOTA)-LNC1010 has been its short half-life and fast rate of clearance.
This combined phase 1/2 clinical trial is designed to initially investigate the safety, tolerability, pharmacokinetics, dosimetry, and preliminary efficacy of 177Lu-LNC1010 in patients with advanced or metastatic SSTR2-positive tumors during the phase 1 portion. The objective is to establish a well-tolerated dose with acceptable side effects. Following this, the phase 2 portion of the trial will involve repeated administration of 177Lu-LNC1010 PRRT at the identified safe fixed dose, aiming to maximize the treatment effect while ensuring patient safety. This phase is set to rigorously evaluate the therapeutic efficacy and potential toxicity of 177Lu-LNC1010 in the management of advanced or metastatic SSTR2-positive tumors.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
30 participants in 4 patient groups
Loading...
Central trial contact
Haojun Chen, PhD; Wei Guo, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal